These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22891299)

  • 1. Dynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cells.
    Hiroshima M; Saeki Y; Okada-Hatakeyama M; Sako Y
    Proc Natl Acad Sci U S A; 2012 Aug; 109(35):13984-9. PubMed ID: 22891299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dimerization of heregulin receptor as observed using single-molecule imaging in living cells].
    Sako Y
    Nihon Yakurigaku Zasshi; 2013 May; 141(5):240-4. PubMed ID: 23665553
    [No Abstract]   [Full Text] [Related]  

  • 3. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H; Akita RW; Sliwkowski MX; Maihle NJ
    Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
    Yang C; Liu Y; Lemmon MA; Kazanietz MG
    Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of heregulin in human cancer.
    Breuleux M
    Cell Mol Life Sci; 2007 Sep; 64(18):2358-77. PubMed ID: 17530167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.
    Kani K; Warren CM; Kaddis CS; Loo JA; Landgraf R
    J Biol Chem; 2005 Mar; 280(9):8238-47. PubMed ID: 15611073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells.
    Noguchi H; Sakamoto C; Wada K; Akamatsu T; Uchida T; Tatsuguchi A; Matsui H; Fukui H; Fujimori T; Kasuga M
    Gastroenterology; 1999 Nov; 117(5):1119-27. PubMed ID: 10535875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heregulin reverses the oligomerization of HER3.
    Landgraf R; Eisenberg D
    Biochemistry; 2000 Jul; 39(29):8503-11. PubMed ID: 10913256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.
    Fitzpatrick VD; Pisacane PI; Vandlen RL; Sliwkowski MX
    FEBS Lett; 1998 Jul; 431(1):102-6. PubMed ID: 9684874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
    Hutcheson IR; Goddard L; Barrow D; McClelland RA; Francies HE; Knowlden JM; Nicholson RI; Gee JM
    Breast Cancer Res; 2011 Mar; 13(2):R29. PubMed ID: 21396094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins.
    Schmidt M; Wels W
    Int J Cancer; 2002 Jan; 97(3):349-56. PubMed ID: 11774287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nectin-like molecule-4/cell adhesion molecule 4 inhibits the ligand-induced dimerization of ErbB3 with ErbB2.
    Mizutani K; Kedashiro S; Maruoka M; Ueda Y; Takai Y
    Sci Rep; 2017 Sep; 7(1):11375. PubMed ID: 28900130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
    Shi X; Xu L; Yu J; Fang X
    Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations.
    Franco-Gonzalez JF; Ramos J; Cruz VL; Martínez-Salazar J
    J Mol Model; 2013 Feb; 19(2):931-41. PubMed ID: 23090500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary dimerization between members of the epidermal growth factor receptor family.
    Gamett DC; Pearson G; Cerione RA; Friedberg I
    J Biol Chem; 1997 May; 272(18):12052-6. PubMed ID: 9115272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
    Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
    BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human epidermal growth factor receptor 3/heregulin interaction inhibitor aptamer discovered using SELEX.
    Yokoyama T; Ando T; Iwamoto R; Fuji D; Yamamoto M; Kawakami T
    Biochem Biophys Res Commun; 2021 May; 553():148-153. PubMed ID: 33770580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.
    van der Woning SP; van Rotterdam W; Nabuurs SB; Venselaar H; Jacobs-Oomen S; Wingens M; Vriend G; Stortelers C; van Zoelen EJ
    J Biol Chem; 2006 Dec; 281(52):40033-40. PubMed ID: 17032651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disabling receptor ensembles with rationally designed interface peptidomimetics.
    Berezov A; Chen J; Liu Q; Zhang HT; Greene MI; Murali R
    J Biol Chem; 2002 Aug; 277(31):28330-9. PubMed ID: 12011054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.